EJP RD Coordinator Daria Julkowska participated to the Panel discussion/ High-level round-table“How do European Partnerships contribute to EU political priorities”.

You will find the video recordings here: https://www.era-learn.eu/news-events/events/european-partnership-stakeholder-forum-one-year-review-of-european-partnership-initiatives-in-horizon-europe

The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has a planned opening date of March 1st, is intended to meet the following specific objectives:

1. Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;
2. Design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;
3. Develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.

The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation. The endpoint in the project should be a completely functional version of the technology suitable for clinical validation, supported by a sound and implementable commercialisation/exploitation strategy.

The funding call has the following deadlines: May 4^th and September 28^th.

For more information: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-eic-2022-transitionchallenges-03

The contest is open for applications until March 8th. The winners will be announced at a dedicated award ceremony in Brussels in 2022.

The prize acknowledges and rewards the most influential and impactful project results under Horizon 2020 (2014-2020) and its predecessor, the 7th Framework Programme (FP7, 2007-2013). The prize will highlight concrete achievements that have a demonstrable value for society, and will celebrate the people who made it happen.

IMPORTANT: The contest is open only to FP7 and Horizon 2020 projects that have ended by the close of the contest and that can provide proof of their impact.

For more information: https://ec.europa.eu/info/research-and-innovation/funding/funding-opportunities/prizes/horizon-impact-award_en

The report contains summaries and quotes from the event’s 70 online live sessions and workshops, as well as from over 200 consultations between participants and Commission representatives.

Notable take-ways of the report include:

• Europe’s collaborative research and innovation at the global scale are key drivers for a greener, healthier and more digital future for all;
• Europe needs more synergies between policies, programmes and instruments at EU, global, national and local level to remain at the forefront of research and innovation, and to be effective at delivering a sustainable future;
• Citizens need to continue having the opportunity to add their voice to the conversation about the future of European research and innovation.

The report’s output will feed into the next co-creating steps of European policy-making in research and innovation, followed by co-implementation.

For more information:

• Event recordings remain available on the event platform.
• The European Research and Innovation Exhibition showcases ground-breaking EU-funded research.

Since the EC recommends that proposals try and take stock of the FAIR guidance and other models and strategies developed by the EJP RD and relevant EU-funded projects, the EJP RD has made available multiple services for prospective applicants

The call is currently accepting proposals that meet the following requirements:

• Aim to develop therapies for rare diseases with no approved therapeutic option, focusing on group(s) of rare diseases with commonalities, such as shared biological features, and should NOT address a single disease only.
• The therapies to be developed may include a broad family of therapeutic interventions, such as small molecule(s), advanced therapy medicinal products, repurposing of existing medicinal products, including non-pharmacological interventions and/or their combinations, as relevant.
• To ensure that the needs of people living with a rare disease are adequately addressed, the involvement of patient representatives in all phases of the research and development process is strongly encouraged.
• Rare infectious diseases and rare cancers are excluded from this topic and will not be considered.

The topic will support proposals covering several different stages in the continuum of the innovation pathway (i.e., translational, preclinical, clinical research, validation in the clinical and/or real-world setting etc.), as relevant.

The funding call has the following deadlines: February 1^st, 2022, and September 6^th, 2022

For more information: